Positive News SentimentPositive NewsNASDAQ:TCRT Alaunos Therapeutics (TCRT) Stock Price, News & Analysis → Your Money is Not Safe (From American Alternative) (Ad) Free TCRT Stock Alerts $1.81 -0.05 (-2.69%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.80▼$1.8850-Day Range$1.40▼$2.7852-Week Range$0.66▼$10.47Volume70,165 shsAverage Volume64,832 shsMarket Capitalization$29.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Alaunos Therapeutics alerts: Email Address Alaunos Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy10.07% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.62Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.10) to ($1.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.54 out of 5 starsMedical Sector890th out of 939 stocksPharmaceutical Preparations Industry419th out of 444 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Alaunos Therapeutics. Previous Next 3.0 Short Interest Percentage of Shares Shorted10.07% of the float of Alaunos Therapeutics has been sold short.Short Interest Ratio / Days to CoverAlaunos Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Alaunos Therapeutics has recently decreased by 6.06%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlaunos Therapeutics does not currently pay a dividend.Dividend GrowthAlaunos Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TCRT. Previous Next 3.1 News and Social Media Coverage News SentimentAlaunos Therapeutics has a news sentiment score of 1.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Alaunos Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for TCRT on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Alaunos Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alaunos Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.18% of the stock of Alaunos Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 27.72% of the stock of Alaunos Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Alaunos Therapeutics are expected to grow in the coming year, from ($2.10) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alaunos Therapeutics is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alaunos Therapeutics is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlaunos Therapeutics has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad American AlternativeYour Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…CLICK HERE TO GET YOUR GUIDE NOW About Alaunos Therapeutics Stock (NASDAQ:TCRT)Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. was founded in 2003 and is headquartered in Houston, Texas.Read More TCRT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCRT Stock News HeadlinesJanuary 31, 2024 | msn.comAlaunos Therapeutics Announces 1-for-15 Reverse Stock SplitJanuary 31, 2024 | investing.comWerewolf Therapeutics Inc (HOWL)March 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…December 28, 2023 | benzinga.comAlaunos Therapeutics Stock (NASDAQ:TCRT) Dividends: History, Yield and DatesNovember 14, 2023 | benzinga.comRecap: Alaunos Therapeutics Q3 EarningsNovember 14, 2023 | investorplace.comWhy Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?November 14, 2023 | finance.yahoo.comAlaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic AlternativesNovember 1, 2023 | morningstar.comAlaunos Therapeutics Inc TCRTMarch 29, 2024 | American Alternative (Ad)Your Money is Not SafeBiden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…August 15, 2023 | msn.comWhy Is Alaunos Therapeutics Sinking Today?August 14, 2023 | finance.yahoo.comAlaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic AlternativesJune 29, 2023 | finance.yahoo.comAlaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic MalignanciesJune 9, 2023 | benzinga.comAlaunos Therapeutics Stock (NASDAQ:TCRT), Insider Trading ActivityMay 26, 2023 | msn.comAlaunos slips 17% on Phase 1/2 data for cancer cell therapyMay 25, 2023 | finance.yahoo.comAlaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual MeetingMay 17, 2023 | uk.news.yahoo.comOne Alaunos Therapeutics Insider Raised Stake By 117% In Previous YearMay 15, 2023 | seekingalpha.comAlaunos Therapeutics upgraded to buy at Wainwright on multiple catalystsMay 13, 2023 | finance.yahoo.comAlaunos Therapeutics, Inc. (NASDAQ:TCRT) Q1 2023 Earnings Call TranscriptMay 11, 2023 | marketwatch.com8-K: Alaunos Therapeutics, Inc.May 10, 2023 | finanznachrichten.deAlaunos Therapeutics, Inc.: Alaunos Therapeutics Reports First Quarter 2023 Financial ResultsMay 10, 2023 | msn.comAlaunos Therapeutics GAAP EPS of -$0.04 in-lineMay 10, 2023 | msn.comRecap: Alaunos Therapeutics Q1 EarningsMay 10, 2023 | finance.yahoo.comAlaunos Therapeutics Reports First Quarter 2023 Financial ResultsMay 3, 2023 | finance.yahoo.comAlaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023April 26, 2023 | finance.yahoo.comAlaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual MeetingApril 25, 2023 | finance.yahoo.comThe past five years for Alaunos Therapeutics (NASDAQ:TCRT) investors has not been profitableApril 2, 2023 | barrons.comAlaunos Therapeutics Inc.See More Headlines Receive TCRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alaunos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today3/28/2024Next Earnings (Estimated)4/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TCRT CUSIPN/A CIK1107421 Webwww.alaunos.com Phone(346) 355-4099Fax617-241-2855Employees34Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.3988) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,730,000.00 Net MarginsN/A Pretax Margin-243,039.98% Return on Equity-140.74% Return on Assets-90.61% Debt Debt-to-Equity RatioN/A Current Ratio2.75 Quick Ratio2.75 Sales & Book Value Annual Sales$2.92 million Price / Sales9.95 Cash FlowN/A Price / Cash FlowN/A Book Value$2.67 per share Price / Book0.68Miscellaneous Outstanding Shares16,050,000Free Float15,058,000Market Cap$29.05 million OptionableOptionable Beta-0.31 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Dale Curtis Hogue Jr. (Age 54)Interim CEO & Director Mr. Michael Wong (Age 44)Vice President of Finance & Principal Accounting Officer Key CompetitorsAptorum GroupNASDAQ:APMSpruce BiosciencesNASDAQ:SPRBAcasti PharmaNASDAQ:ACSTAcurx PharmaceuticalsNASDAQ:ACXPFSD PharmaNASDAQ:HUGEView All CompetitorsInsiders & InstitutionsMSD Partners L.P.Sold 7,575,758 shares on 2/20/2024Ownership: 94.402%Citadel Advisors LLCSold 39,100 shares on 2/15/2024Ownership: 0.000%Commerce BankSold 22,000 shares on 2/9/2024Ownership: 2.723%Magnolia Capital Advisors LLCSold 31,462 shares on 2/2/2024Ownership: 0.167%Kevin S Sr. BoyleSold 4,534 sharesTotal: $9,521.40 ($2.10/share)View All Insider TransactionsView All Institutional Transactions TCRT Stock Analysis - Frequently Asked Questions Should I buy or sell Alaunos Therapeutics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alaunos Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TCRT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRT, but not buy additional shares or sell existing shares. View TCRT analyst ratings or view top-rated stocks. How have TCRT shares performed in 2024? Alaunos Therapeutics' stock was trading at $1.0605 at the start of the year. Since then, TCRT shares have increased by 70.7% and is now trading at $1.81. View the best growth stocks for 2024 here. When is Alaunos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024. View our TCRT earnings forecast. How were Alaunos Therapeutics' earnings last quarter? Alaunos Therapeutics, Inc. (NASDAQ:TCRT) released its earnings results on Tuesday, November, 14th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by $0.15. When did Alaunos Therapeutics' stock split? Alaunos Therapeutics shares reverse split on Thursday, February 1st 2024. The 1-15 reverse split was announced on Thursday, February 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Alaunos Therapeutics' major shareholders? Alaunos Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include MSD Partners L.P. (94.40%), Commerce Bank (2.72%), Magnolia Capital Advisors LLC (0.17%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Kevin S Sr Boyle and Robert W Postma. View institutional ownership trends. How do I buy shares of Alaunos Therapeutics? Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TCRT) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeYour Money is Not SafeAmerican AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyThe ONE AI Sock to own now. (It’s not Nvidia.)Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.